Regeneron registers two new cemiplimab trials in skin cancer and early lung cancer

Regeneron posted two new clinical trial registrations this week, both involving cemiplimab and both not yet recruiting.

• A Phase 2 platform trial (NCT07808515) will test an experimental Regeneron drug called cemiplimab given alone or in combination with other anti-cancer drugs to treat locally advanced basal cell carcinoma.¹ The study plans to enroll 135 participants (estimated)¹ and has an estimated start date of October 15, 2026.
• A separate Phase 2 study called RADICAL-IO (NCT07808138), sponsored by The Netherlands Cancer Institute with Regeneron as a collaborator, will evaluate whether selected patients with a high chance to respond to immunotherapy can be treated with immunotherapy alone, thereby evaluating whether these patients can be cured without surgery or radiotherapy.² Participants will receive three cycles of 350 milligrams of cemiplimab intravenously every three weeks followed by a radiological and metabolic response evaluation with respectively CT and [18F]FDG-PET², with an estimated enrollment of 30 participants.